Overview
The nation is facing competing public health issues: the need to treat a large number of Americans with acute and chronic pain vs the crisis of opioid abuse. Pri-Med’s P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-25 curriculum focuses on improving practitioners’ ability to recognize, diagnose, and classify pain; educating clinicians on the full spectrum of pain management options, including non-opioid pharmacologic interventions; and providing risk reduction strategies through integration of opioids into individualized pain management plans. Clinicians will learn to recognize signs and symptoms of opioid dependence and abuse in order to optimally manage patients’ pain and medication use.
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies.
Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies.
This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
The session "P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025: Part 3" (1.50 hour) is designed to satisfy state licensure requirements (MD/PA/NP) on Controlled Substances - Pain Management and the Prescription of Opioids and is approved for Ethics and Professional Responsibility credit (MD/DO) in Texas, as well as training requirements for the DEA Mate Act; LA: This activity is approved for Controlled Substances by the Louisiana State Board of Nursing (NP Only)
Learning Objectives
- Recognize best practices to reduce the risks associated with prescription of opioid analgesics, including safe storage and disposal
- Anticipate and manage adverse effects of opioid use including signs of opioid overdose and the use of naloxone
- Select approaches to safely initiate opioids for the treatment of acute pain and chronic pain
- Identify strategies for ongoing safe and effective use of opioids in patients with chronic pain, including titration, referral, and discontinuation, when appropriate
EDUCATIONAL PARTNERS
Miller Medical Communications, LLC
Equity Commons
SUPPORTED BY
Opioid Analgesic REMS Program Companies